{"id":"W4415322256","doi":"10.1016/j.annonc.2025.10.010","title":"Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Memorial Sloan-Kettering Cancer Center; Merck","keywords":"Clinical trial; Phase (matter); Phases of clinical research; Cell; Safety profile","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002476598,0.0008026651,0.002425549,0.0003881519,0.0005474673,0.001464817,0.0008396079,0.001171271,0.003551463],"category_scores_gemma":[0.001283875,0.0003172213,0.002124175,0.0005433016,0.0005980617,0.001553749,0.000363969,0.003890618,0.0009596203],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001540587,"about_ca_system_score_gemma":0.001246947,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00152999,"about_ca_topic_score_gemma":0.007113446,"domain_scores_codex":[0.9993396,0.0003412391,0.00003103105,0.00008925599,0.00006045771,0.0001385064],"domain_scores_gemma":[0.9992796,0.0001820506,0.0001519759,0.00007290163,0.00004787681,0.0002655903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6859654,0.01682099,0.007543147,0.003004126,0.005338789,0.00016909,0.0003006186,0.002801593,0.01378997,0.001034619,0.0150454,0.2481862],"study_design_scores_gemma":[0.7794028,0.1701608,0.02457828,0.0004100313,0.003363346,0.0004972818,0.0001978037,0.003127482,0.003304998,0.001238915,0.01364658,0.00007167037],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9627881,0.0222586,0.0008586941,0.001595136,0.0004994776,0.001739354,0.003885597,0.0001809176,0.006194085],"genre_scores_gemma":[0.978673,0.007799655,0.002189979,0.002027476,0.000393589,0.001652746,0.004111845,0.00004571169,0.003105746],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003551463,"threshold_uncertainty_score":0.0130977,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1515518232999306,"score_gpt":0.4186534860126829,"score_spread":0.2671016627127523,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}